A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas

Journal of Neuro-Oncology

Volumn 110, Issue 2, 2012, Pages 245-250

  Nghiemphu, Phioanh Leia ^a   Lai, Albert ^a   Green, Richard M ^b   Reardon, David A ^c   Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kaiser Permanente ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Combination study; Erlotinib; Recurrent gliomas; Sirolimus

Indexed keywords

ERLOTINIB; RAPAMYCIN;

ADULT; AGED; ANOREXIA; ARTICLE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MENTAL DISEASE; MORNING DOSAGE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; RECURRENT CANCER; SKIN INJURY; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; QUINAZOLINES; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 84867854266     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0960-y     Document Type: Article

References (26)

1. ACS (2010) Cancer facts & figures. American cancer society, Atlanta
2. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
3. Wong E et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572
4. Lamborn KR et al (2008) Progression-free survival:an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncol 10(2):162-170
5. Friedman HS et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733-4740
6. Kreisl TN et al (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-Oncol 13(10):1143-1150
7. Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19(18 Suppl):32S-40S
8. Maity A et al (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60(20):5879-5886
9. Humphrey PA et al (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48(8):2231-2238
10. Libermann TA et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313(5998):144-147
11. Steck PA et al (1986) Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J Cell Biochem 32(1):1-10
12. Lee JC et al (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3(12):e485
13. The Cancer Genome Atlas (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
14. Wick W et al (2011) Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncol 13(6):566-579
15. Mellinghoff IK et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012-2024
16. Cloughesy TF et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8
17. Stommel JM et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287-290
18. Doherty L et al (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67(1):156-158
19. Reardon DA et al (2010) Phase II trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96(2):219-230
20. Yung WK et al (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncol 12(10):1061-1070
21. Gilbert MR (2011) Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol 38(Suppl 4):S21-S33
22. Prados M et al Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol 27:(Suppl 15) (suppl; abstr 2005)
23. Reardon DA et al (2012) Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol 69(1):281-287
24. Clarke JL et al (2010) High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99(2):283-286
25. Vivanco I et al (2012) Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-471
26. EGFR inhibition using high dose administration of erlotinib weekly for recurrent malignant Gliomas with EGFR variant III mutation. 2011 [cited 2012 February]; Available from: http://clinicaltrials.gov/ct2/show/NCT01257594?term= erlotinib+AND+new+York+AND+glioblastoma&rank=5. Accessed 21 Aug 2012